T1	Participants 285 349	patients with diabetes receiving standard treatment for diabetes
T2	Participants 691 734	patients with diabetes and A1C of >or=8-10%
T3	Participants 862 887	placebo-adjusted (n = 182
T4	Participants 753 760	n = 171
T5	Participants 968 1040	patients with FPG of 150-400 mg/dl at randomization, ranolazine (n = 131
T6	Participants 1056 1072	placebo (n = 147
